SCHEMBL17602191

SCHEMBL17602191

COC(C)c1ccc(C(N)c2ccc(OCc3ccccc3)cc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALOX5 P09917 1/20 0.51
MAOB P27338 2/20 0.50
GAA P10253 1/20 0.50
MAPT P10636 1/20 0.50
MAOA P21397 1/20 0.50
RAB9A P51151 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
L3MBTL1 Q9Y468 1/20 0.50
LTA4H P09960 3/20 0.49
LMNA P02545 1/20 0.47
CYP1A2 P05177 1/20 0.47
PTGS1 P23219 1/20 0.47
SLC6A2 P23975 1/20 0.47
CYP2C19 P33261 1/20 0.47
PTGS2 P35354 1/20 0.47
SLC6A3 Q01959 1/20 0.47
HIF1A Q16665 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
BCHE P06276 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9547764 0.92 LMNA (0.55) ALOX5MAOBGAAMAPTMAOA
SCHEMBL9547773 0.88 ACACB (0.55) ALOX5MAOBGAAMAPTMAOA
SCHEMBL11838902 0.86 MAOB (0.61) ALOX5MAOBGAAMAPTMAOA
SCHEMBL17602195 0.83 ALOX5 (0.49) ALOX5MAOBMAOALMNACYP1A2
SCHEMBL17602196 0.83 BCHE (0.51) ALOX5MAOBGAAMAPTMAOA
SCHEMBL6376299 0.81 MAOB (0.59) ALOX5MAOBGAAMAPTMAOA
SCHEMBL7768214 0.81 MAOB (0.59) ALOX5MAOBGAAMAPTMAOA
SCHEMBL17602193 0.80 MAPT (0.65) GAAMAPTRAB9ASMN1; SMN2L3MBTL1
Hydrochloric Acid SCHEMBL8069808 0.80 MAOB (0.59) ALOX5MAOBGAAMAPTMAOA
Hydrochloric Acid SCHEMBL7597068 0.80 MAOB (0.59) ALOX5MAOBGAAMAPTMAOA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250066355-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2025-02-27 US disclosed
US-12172998-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2024-12-24 US disclosed
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2023-04-20 US disclosed
US-11535616-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC (US) 2022-12-27 US disclosed
EP-3453710-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-09-21 EP disclosed
EP-3430008-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-05-18 EP disclosed
EP-3193601-B1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RES INC (US) 2022-01-05 EP disclosed
US-20210009585-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2021-01-14 US disclosed
US-10815234-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2020-10-27 US disclosed
US-20200199122-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2020-06-25 US disclosed
US-20180297999-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-10-18 US disclosed
US-10030017-B2 Histone demethylase inhibitors CELGENE QUANTICEL RESEARCH, INC. (US) 2018-07-24 US disclosed
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2018-06-14 US disclosed
WO-2017161012-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-09-21 WO disclosed
US-20170240546-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. (US) 2017-08-24 US disclosed
EP-3193601-A1 HISTONE DEMETHYLASE INHIBITORS Celgene Quanticel Research, Inc. (US) 2017-07-26 EP disclosed
US-9643965-B2 Histone demethylase inhibitors Celgene Quantical Research, Inc. (US) 2017-05-09 US disclosed
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-07-07 US disclosed
US-20160083379-A1 HISTONE DEMETHYLASE INHIBITORS CELGENE QUANTICEL RESEARCH, INC. 2016-03-24 US disclosed
WO-2016044429-A1 HISTONE DEMETHYLASE INHIBITORS Quanticel Pharmaceuticals, Inc. (US) 2016-03-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160194323-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A ALOX5 1638/4885MAOB 612/4885GAA 2038/4885
US-12172998-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5C ALOX5 1780/4885MAOB 594/4885GAA 1975/4885
US-10030017-B2 Histone demethylase inhibitors KDM1B, KDM5C, KDM1A ALOX5 1638/4885MAOB 612/4885GAA 2038/4885
US-20160083379-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C ALOX5 1780/4885MAOB 594/4885GAA 1975/4885
US-11535616-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5C ALOX5 1780/4885MAOB 594/4885GAA 1975/4885
US-20170240546-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C ALOX5 1780/4885MAOB 594/4885GAA 1975/4885
US-20200199122-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C ALOX5 1780/4885MAOB 594/4885GAA 1975/4885
US-20180162857-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A ALOX5 1638/4885MAOB 612/4885GAA 2038/4885
US-20230117519-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C ALOX5 1780/4885MAOB 594/4885GAA 1975/4885
US-20180297999-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM5C, KDM1A ALOX5 1638/4885MAOB 612/4885GAA 2038/4885
US-20210009585-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C ALOX5 1780/4885MAOB 594/4885GAA 1975/4885
US-20250066355-A1 HISTONE DEMETHYLASE INHIBITORS KDM1B, KDM1A, KDM5C ALOX5 1780/4885MAOB 594/4885GAA 1975/4885
US-10815234-B2 Histone demethylase inhibitors KDM1B, KDM1A, KDM5C ALOX5 1780/4885MAOB 594/4885GAA 1975/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.